schliessen

Filtern

 

Bibliotheken

Drug Delivery System of Anti-fungal and Parasitic Agents

The antifungal agents for systemic mycoses are only a few in number. Among them amphotericin-B is still the most widely used drug, but substantial side effects including nephrotoxicity limits its clinical usefulness. Efforts to lower the toxicity are synthesis of AMPH-B analogues such as AMPH-B este... Full description

Journal Title: Current Pharmaceutical Design 2002, Vol.8(6), p.433-440
Main Author: Maesaki, Shigefumi
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1381-6128 ; E-ISSN: 1873-4286 ; DOI: 10.2174/1381612023395916
Link: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=13816128&volume=8&issue=6&spage=433
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: bentham10.2174/1381612023395916
title: Drug Delivery System of Anti-fungal and Parasitic Agents
format: Article
creator:
  • Maesaki, Shigefumi
subjects:
  • Anti-Fungal
  • Parasitic Agents
  • Liposome-Encapsulated Antifungal Agents
  • Liposme-Enacapsulated Antiparasitic Agents
ispartof: Current Pharmaceutical Design, 2002, Vol.8(6), p.433-440
description: The antifungal agents for systemic mycoses are only a few in number. Among them amphotericin-B is still the most widely used drug, but substantial side effects including nephrotoxicity limits its clinical usefulness. Efforts to lower the toxicity are synthesis of AMPH-B analogues such as AMPH-B esters and encapsulation in lipid vesicles in the forms of liposomal AMPH-B (AmBisome), amphotericin-B lipid complex (Abelcet), amphotericin-B colloidal dispersion (Amphocil) and intralipid AMPH-B. The newer formulations are effective against wide range of fungi, may be given in higher doses and nephrotoxicity is lowered. Although all of them showed comparable efficacies, a standard formulation is yet to be determined. In Japan, studies on efficacies of lipid nanosphere-encapsulated AMPH-B are in progress. Special drug career systems and dosage forms, such as nanoparticles and liposomes hold the promise of overcoming the pharmacokinetic limitations. Nanoparticles are stable, solid colloidal particles consisting of macromolecular material and vary in size. Nanoparticles represent an interesting carrier system for the specific enrichment in macrophage containing organs like liver and spleen. Injectable nanoparticle carriers have important potential applications as in sitespecific drug delivery. Modifications of liposomes in order to avoid uptake by RES, thus increase targetability has been attempted. A novel targetable liposome 34A-PEG-L modified with polyethylene glycol conjugated with MoAb, 34A specific to murine pulmonary epithelia has been evaluated in murine pulmonary aspergillosis. 34A-PEG-L-AmB showed higher tissue concentration and comparable efficacy than other AMPH-B formulations.
language: eng
source:
identifier: ISSN: 1381-6128 ; E-ISSN: 1873-4286 ; DOI: 10.2174/1381612023395916
fulltext: fulltext
issn:
  • 1381-6128
  • 13816128
  • 1873-4286
  • 18734286
url: Link


@attributes
ID207327521
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.2174/1381612023395916
sourceidbentham
recordidTN_bentham10.2174/1381612023395916
sourceformatXML
sourcesystemOther
pqid215123433
ingidben/cpd/2002/00000008/00000006/art00002
display
typearticle
titleDrug Delivery System of Anti-fungal and Parasitic Agents
creatorMaesaki, Shigefumi
ispartofCurrent Pharmaceutical Design, 2002, Vol.8(6), p.433-440
identifier
subjectAnti-Fungal ; Parasitic Agents ; Liposome-Encapsulated Antifungal Agents ; Liposme-Enacapsulated Antiparasitic Agents
descriptionThe antifungal agents for systemic mycoses are only a few in number. Among them amphotericin-B is still the most widely used drug, but substantial side effects including nephrotoxicity limits its clinical usefulness. Efforts to lower the toxicity are synthesis of AMPH-B analogues such as AMPH-B esters and encapsulation in lipid vesicles in the forms of liposomal AMPH-B (AmBisome), amphotericin-B lipid complex (Abelcet), amphotericin-B colloidal dispersion (Amphocil) and intralipid AMPH-B. The newer formulations are effective against wide range of fungi, may be given in higher doses and nephrotoxicity is lowered. Although all of them showed comparable efficacies, a standard formulation is yet to be determined. In Japan, studies on efficacies of lipid nanosphere-encapsulated AMPH-B are in progress. Special drug career systems and dosage forms, such as nanoparticles and liposomes hold the promise of overcoming the pharmacokinetic limitations. Nanoparticles are stable, solid colloidal particles consisting of macromolecular material and vary in size. Nanoparticles represent an interesting carrier system for the specific enrichment in macrophage containing organs like liver and spleen. Injectable nanoparticle carriers have important potential applications as in sitespecific drug delivery. Modifications of liposomes in order to avoid uptake by RES, thus increase targetability has been attempted. A novel targetable liposome 34A-PEG-L modified with polyethylene glycol conjugated with MoAb, 34A specific to murine pulmonary epithelia has been evaluated in murine pulmonary aspergillosis. 34A-PEG-L-AmB showed higher tissue concentration and comparable efficacy than other AMPH-B formulations.
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://www.eurekaselect.com/openurl/content.php?genre=article&issn=13816128&volume=8&issue=6&spage=433$$EView_record_at_Bentham_Science
openurlfulltext$$Topenurlfull_article
search
creatorcontribMaesaki, Shigefumi
titleDrug Delivery System of Anti-fungal and Parasitic Agents
descriptionThe antifungal agents for systemic mycoses are only a few in number. Among them amphotericin-B is still the most widely used drug, but substantial side effects including nephrotoxicity limits its clinical usefulness. Efforts to lower the toxicity are synthesis of AMPH-B analogues such as AMPH-B esters and encapsulation in lipid vesicles in the forms of liposomal AMPH-B (AmBisome), amphotericin-B lipid complex (Abelcet), amphotericin-B colloidal dispersion (Amphocil) and intralipid AMPH-B. The newer formulations are effective against wide range of fungi, may be given in higher doses and nephrotoxicity is lowered. Although all of them showed comparable efficacies, a standard formulation is yet to be determined. In Japan, studies on efficacies of lipid nanosphere-encapsulated AMPH-B are in progress. Special drug career systems and dosage forms, such as nanoparticles and liposomes hold the promise of overcoming the pharmacokinetic limitations. Nanoparticles are stable, solid colloidal particles consisting of macromolecular material and vary in size. Nanoparticles represent an interesting carrier system for the specific enrichment in macrophage containing organs like liver and spleen. Injectable nanoparticle carriers have important potential applications as in sitespecific drug delivery. Modifications of liposomes in order to avoid uptake by RES, thus increase targetability has been attempted. A novel targetable liposome 34A-PEG-L modified with polyethylene glycol conjugated with MoAb, 34A specific to murine pulmonary epithelia has been evaluated in murine pulmonary aspergillosis. 34A-PEG-L-AmB showed higher tissue concentration and comparable efficacy than other AMPH-B formulations.
subject
0anti-fungal
1parasitic agents
2liposome-encapsulated antifungal agents
3liposme-enacapsulated antiparasitic agents
general
010.2174/1381612023395916
1Bentham Science Publishers Ltd.
2English
3Bentham Science - Journals
sourceidbentham
recordidbentham10.2174/1381612023395916
issn
01381-6128
113816128
21873-4286
318734286
rsrctypearticle
creationdate2002
addtitleCurrent Pharmaceutical Design
searchscopebentham
scopebentham
lsr30VSR-Enriched:[pqid, ingid]
sort
titleDrug Delivery System of Anti-fungal and Parasitic Agents
authorMaesaki, Shigefumi
creationdate20020300
facets
frbrgroupid7862069841718374077
frbrtype5
languageeng
creationdate2002
topic
0anti-fungal
1parasitic agents
2liposome-encapsulated antifungal agents
3liposme-enacapsulated antiparasitic agents
collectionBentham Science - Journals
prefilterarticles
rsrctypearticles
creatorcontribMaesaki, Shigefumi
jtitleCurrent Pharmaceutical Design
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulastMaesaki
aufirstShigefumi
auMaesaki, Shigefumi
atitleDrug Delivery System of Anti-fungal and Parasitic Agents
jtitleCurrent Pharmaceutical Design
risdate200203
volume8
issue6
spage433
epage440
pages433-440
issn1381-6128
eissn1873-4286
formatjournal
genrearticle
ristypeJOUR
abstractThe antifungal agents for systemic mycoses are only a few in number. Among them amphotericin-B is still the most widely used drug, but substantial side effects including nephrotoxicity limits its clinical usefulness. Efforts to lower the toxicity are synthesis of AMPH-B analogues such as AMPH-B esters and encapsulation in lipid vesicles in the forms of liposomal AMPH-B (AmBisome), amphotericin-B lipid complex (Abelcet), amphotericin-B colloidal dispersion (Amphocil) and intralipid AMPH-B. The newer formulations are effective against wide range of fungi, may be given in higher doses and nephrotoxicity is lowered. Although all of them showed comparable efficacies, a standard formulation is yet to be determined. In Japan, studies on efficacies of lipid nanosphere-encapsulated AMPH-B are in progress. Special drug career systems and dosage forms, such as nanoparticles and liposomes hold the promise of overcoming the pharmacokinetic limitations. Nanoparticles are stable, solid colloidal particles consisting of macromolecular material and vary in size. Nanoparticles represent an interesting carrier system for the specific enrichment in macrophage containing organs like liver and spleen. Injectable nanoparticle carriers have important potential applications as in sitespecific drug delivery. Modifications of liposomes in order to avoid uptake by RES, thus increase targetability has been attempted. A novel targetable liposome 34A-PEG-L modified with polyethylene glycol conjugated with MoAb, 34A specific to murine pulmonary epithelia has been evaluated in murine pulmonary aspergillosis. 34A-PEG-L-AmB showed higher tissue concentration and comparable efficacy than other AMPH-B formulations.
pubBentham Science Publishers Ltd.
doi10.2174/1381612023395916
date2002-03